Core Insights - InspireMD, Inc. has appointed Dr. Peter A. Soukas as Chief Medical Officer to enhance its clinical and medical strategy during a critical phase for the company [1][2] Company Overview - InspireMD is focused on developing the CGuard® Prime carotid stent system aimed at preventing strokes, utilizing proprietary MicroNet™ mesh technology to achieve superior acute results and long-term outcomes [5] Leadership Appointment - Dr. Soukas brings extensive experience in vascular intervention, serving as Director of Vascular Medicine at The Miriam Hospital and Associate Professor at Brown University, where he founded the Vascular and Endovascular Medicine Fellowship Program [2][3] - His background includes being a principal investigator in over 24 carotid stenting trials and more than 150 endovascular trials, along with delivering over 300 invited lectures and publishing numerous peer-reviewed papers [3] Strategic Vision - Dr. Soukas expressed his commitment to guiding InspireMD in clinical and medical topics, aiming to enhance awareness of the CGuard Prime stent platform and improve patient care through collaboration with clinical partners [4]

Core Insights - InspireMD, Inc. has raised approximately $58 million through a PIPE financing and warrant exercise, following the FDA's approval of its CGuard® Prime carotid stent system [1][2][3] - The PIPE financing generated gross proceeds of $40.1 million, with participation from existing and new investors, and the exercise of warrants contributed an additional $17.9 million [2][3] - The funds will be utilized for operations including sales and marketing, research and development, and general corporate purposes [4] Financing Details - The PIPE financing involved the issuance of 16,556,184 shares of common stock at a purchase price of $2.42 per share [2] - The transaction is expected to close by August 1, 2025, subject to customary conditions [3] - BofA Securities acted as the exclusive placement agent for the PIPE [4] Strategic Objectives - The CEO of InspireMD stated that the transaction strengthens the company's balance sheet and positions it for rapid commercial growth in the carotid intervention market [3] - The company aims to leverage its proprietary MicroNet™ mesh technology to establish its products as the industry standard for carotid stenting [7]